Loading...

Brilliant Violet 421™ anti-mouse CD45 Antibody

Pricing & Availability
Clone
30-F11 (See other available formats)
Regulatory Status
RUO
Other Names
T200, Ly-5, LCA
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
30-F11_BV421_051911
C57BL/6 mouse splenocytes were stained with CD45 (clone 30-F11) Brilliant Violet 421™ (filled histogram) or rat IgG2b Brilliant Violet 421™ isotype control (open histogram).
  • 30-F11_BV421_051911
    C57BL/6 mouse splenocytes were stained with CD45 (clone 30-F11) Brilliant Violet 421™ (filled histogram) or rat IgG2b Brilliant Violet 421™ isotype control (open histogram).
See Brilliant Violet 421™ spectral data
Cat # Size Price Quantity Check Availability Save
103133 125 µL £125
Check Availability


Need larger quantities of this item?
Request Bulk Quote
103134 50 µg £166
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD45 is a 180-240 kD glycoprotein also known as the leukocyte common antigen (LCA), T200, or Ly-5. It is a member of the protein tyrosine phosphatase (PTP) family, expressed on all hematopoietic cells except mature erythrocytes and platelets. There are different isoforms of CD45 that arise from variable splicing of exons 4, 5, and 6, which encode A, B, and C determinants, respectively. CD45 plays a key role in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation state of the cell as well as cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

SB - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45.

Additional reported applications (for relevant formats) include: immunoprecipitation3, complement-dependent cytotoxicity1,5, immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections)4,6, Western blotting7, and spatial biology (IBEX)10,11. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103163 and 103164).

Additional Product Notes

Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

Application References

(PubMed link indicates BioLegend citation)
  1. Podd BS, et al. 2006. J. Immunol. 176:6532. (FC, CMCD) PubMed
  2. Haynes NM, et al. 2007. J. Immunol. 179:5099. (FC)
  3. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IP)
  4. Simon DI, et al. 2000. J. Clin. Invest. 105:293. (IHC)
  5. Seaman WE. 1983. J. Immunol. 130:1713. (CMCD)
  6. Cornet A, et al. 2001. P. Natl. Acad. Sci. USA 98:13306. (IHC)
  7. Tsuboi S and Fukuda M. 1998. J. Biol. Chem. 273:30680. (WB) PubMed
  8. Liu F, et al. 2012. Blood. 119:3295. PubMed
  9. Pelletier AN, et al. 2012. J. Immunol. 188:5561. PubMed
  10. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  11. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Crncec I, et al. 2018. Mol Oncol. 12:514. PubMed
  2. Kramann R, et al. 2018. JCI Insight. 3. PubMed
  3. Barrow AD et al. 2018. Cell. 172(3):534-548 . PubMed
  4. Wakabayashi T et al. 2018. Cell stem cell. 22(3):384-397 . PubMed
  5. Zwick M, et al. 2019. Front Immunol. 10:222. PubMed
  6. Kurelac I, et al. 2019. Nat Commun. 10:903. PubMed
  7. Durré T, et al. 2018. Nat Commun. 9:5178. PubMed
  8. Li Q, et al. 2019. Front Cell Neurosci. 12:520. PubMed
  9. Glodde N et al. 2017. Immunity. 47(4):789-802 . PubMed
  10. Mamedov MR, et al. 2018. Immunity. 48:350. PubMed
  11. Parlet CP, et al. 2019. Cell Rep. 27:187. PubMed
  12. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
  13. Karlen SJ, et al. 2018. J Neuroinflammation. 15:344. PubMed
  14. Shmeleva EV, et al. 2019. Front Immunol. 10:1780. PubMed
  15. Saleh MM, et al. 2019. Cell Host Microbe. 25:756. PubMed
  16. Dahlgren MW et al. 2019. Immunity. 50(3):707-722 . PubMed
  17. Meng Michelle Xu et al. 2017. Immunity. 47(2):363-373 . PubMed
  18. Ulland TK et al. 2017. Cell. 170(4):649-663 . PubMed
  19. Mao W, et al. 2019. J Immunother Cancer. 0.484027778. PubMed
  20. Katara GK, et al. 2020. Mol Oncol. 0.729861111. PubMed
  21. Bersini S, et al. 2020. Life Sci Alliance. 3:e201900623. PubMed
  22. Cullis J, et al. 2017. Cancer Immunol Res. 5:182. PubMed
  23. Deczkowska A, et al. 2017. Nat Commun. 8:717. PubMed
  24. Kobayashi T, et al. 2019. Cell. 176:982. PubMed
  25. Saika A, et al. 2020. FASEB Bioadv. 2:59. PubMed
  26. Lee H, et al. 2020. Cell Metabolism. 31(4):822-836. PubMed
  27. Süß P, et al. 2020. Cell Reports. 30(12):4082-4095. PubMed
  28. Song WM, et al. 2018. J Exp Med. 215:745. PubMed
  29. Kobayashi H, et al. 2020. STAR Protoc. 1:100078. PubMed
  30. Zahr A, et al. 2016. Nat Commun. 7:10363. PubMed
  31. Chu C, et al. 2016. Dis Model Mech. 9: 473-481. PubMed
  32. Liu Q, et al. 2016. Cell Death Dis. 1.93125. PubMed
  33. Mittal S, et al. 2016. Stem Cell Reports. 7:583-590. PubMed
  34. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  35. Li J, et al. 2020. Elife. 9:00. PubMed
  36. Goh W, et al. 2020. Cell Rep. 33:108285. PubMed
  37. Hu B, et al. 2020. J Clin Invest. 130:3483. PubMed
  38. Hirata SI, et al. 2020. Allergy. 75:1939. PubMed
  39. Hagan AS, et al. 2020. Development. 147:00:00. PubMed
  40. Dobson HE, et al. 2020. Mucosal Immunol. 0.901388889. PubMed
  41. Naito H, et al. 2020. Nature Protocols. 15(3):1066-1081. PubMed
  42. Zheng H, et al. 2021. Frontiers in Cell and Developmental Biology. 9:641527. PubMed
  43. Zheng H, et al. 2021. Frontiers in Immunology. 12:645100. PubMed
  44. Dinh HQ, et al. 2020. Immunity. 53(2):319-334.e6. PubMed
  45. Omori S, et al. 2020. Cell Metabolism. 32(5):814-828.e6. PubMed
  46. Guldner IH, et al. 2020. Cell. 183(5):1234-1248.e25. PubMed
  47. Nishimura T, et al. 2020. Cell Stem Cell. 28(1):141-149.e3. PubMed
  48. Engler AE, et al. 2020. Cell Reports. 33(13):108553. PubMed
  49. Dubrot J, et al. 2021. Immunity. 54(3):571-585.e6. PubMed
  50. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  51. Chuang CH, et al. 2020. Cancer Research. 81:567. PubMed
  52. Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed
  53. Siolas D, et al. 2021. Cell Reports. 36:109578. PubMed
  54. Suter EC, et al. 2021. Cell Reports. 36(8):109587. PubMed
  55. Webster HC, et al. 2020. J Immunol Methods. 112702:477. PubMed
  56. Boeck M, et al. 2020. Glia. 1859:68. PubMed
  57. Usui-Ouchi A, et al. 2020. Proc Natl Acad Sci U S A. 28297:117. PubMed
  58. Zhang Y, et al. 2021. Commun Biol. 344:4. PubMed
  59. de Lucía Finkel P, et al. 2021. Sci Rep. 11:12233. PubMed
  60. Ben-Yehuda H, et al. 2021. Mol Neurodegener. 16:39. PubMed
  61. Deng J, et al. 2021. JCI Insight. 6:146133. PubMed
  62. Ombrato L, et al. 2021. Nat Protoc. 16:872. PubMed
  63. Pan YC, et al. 2021. Mol Ther Oncolytics. 20:175. PubMed
  64. Schlecht A, et al. 2021. Front Cell Dev Biol. 8:618598. PubMed
  65. Zhang X, et al. 2021. Front Pharmacol. 12:629513. PubMed
  66. Jiang H, et al. 2021. Oncoimmunology. 10:1943180. PubMed
  67. Carbone C, et al. 2021. J Immunother Cancer. 9:. PubMed
  68. Shibuya M, et al. 2021. iScience. 24:103131. PubMed
  69. Karlsson J, et al. 2021. Adv Funct Mater. 31:. PubMed
  70. Miller EB, et al. 2021. J Neuroinflammation. 18:235. PubMed
  71. Sharma GP, et al. 2021. PLoS One. 16:e0259042. PubMed
  72. Mathur S, et al. 2021. JCI Insight. 6:. PubMed
  73. Sakamoto K, et al. 2022. STAR Protoc. 3:101052. PubMed
  74. Nagatake T, et al. 2022. Mucosal Immunol. 15:289. PubMed
  75. Galán-Díez M, et al. 2022. Cancer Discov. . PubMed
  76. Nagatake T, et al. 2021. Int Immunol. 33:171. PubMed
  77. Wieghofer P, et al. 2021. EMBO J. 40:e105123. PubMed
  78. Agalave NM, et al. 2021. Front Immunol. 12:642420. PubMed
  79. Yi H, et al. 2021. Front Immunol. 12:719189. PubMed
  80. Zhang P, et al. 2021. J Neuroinflammation. 18:215. PubMed
  81. Celorrio M, et al. 2022. Acta Neuropathol Commun. 10:10. PubMed
  82. Bell BJ, et al. 2022. Brain Behav Immun Health. 23:100478. PubMed
  83. Helm M, et al. 2022. Life (Basel). 12:. PubMed
  84. Perdigoto AL, et al. 2022. JCI Insight. 7:. PubMed
  85. Boddupalli CS, et al. 2022. Elife. 11:. PubMed
  86. Cui Z, et al. 2022. Bone Res. 10:58. PubMed
  87. Aktories P, et al. 2022. Cell Rep Methods. 2:100260. PubMed
  88. Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed
  89. Zheng X, et al. 2020. Int J Cancer. 146:1730. PubMed
  90. Sakamoto K, et al. 2021. Immunity. 54:2321. PubMed
  91. Schlecht A, et al. 2021. Int J Mol Sci. 22:. PubMed
  92. Ma Z, et al. 2022. Methods Mol Biol. 2471:49. PubMed
  93. Palma A, et al. 2022. Front Cell Dev Biol. 10:841548. PubMed
  94. Hoover AR, et al. 2022. Clin Transl Med. 12:e937. PubMed
  95. Scheyltjens I, et al. 2022. Nat Protoc. 17:2354. PubMed
  96. Bratti M, et al. 2022. Front Immunol. 13:1029759. PubMed
  97. Nishiga Y, et al. 2022. Nat Cancer. 3:1351. PubMed
  98. Haase C, et al. 2022. Nat Methods. 19:1622. PubMed
  99. Deng P, et al. 2022. J Clin Invest. 132: . PubMed
  100. Balood M, et al. 2022. Nature. 611:405. PubMed
  101. Millar FR, et al. 2022. Cell Rep. 41:111596. PubMed
  102. Zhuang L, et al. 2022. J Am Heart Assoc. 11:e027228. PubMed
  103. Choi H, et al. 2023. J Nanobiotechnology. 21:5. PubMed
  104. Pariury H, et al. 2023. Haematologica. :. PubMed
  105. Tanaka T, et al. 2023. Nat Immunol. 24:439. PubMed
  106. Gomez-Salinero JM, et al. 2022. Cell Stem Cell. 29:593. PubMed
  107. Hentzschel F, et al. 2022. Sci Adv. 8:eabm7348. PubMed
  108. Reticker-Flynn NE, et al. 2022. Cell. 185:1924. PubMed
  109. Hailemichael Y, et al. 2022. Cancer Cell. 40:509. PubMed
  110. Bohrer AC, et al. 2022. Cell Rep. 40:111144. PubMed
  111. Shiroshita K, et al. 2022. Cell Rep Methods. 2:100354. PubMed
  112. Gómez-Salinero JM, et al. 2022. Nat Cardiovasc Res. 1:882. PubMed
  113. Ando M, et al. 2021. Cancer Res Commun. 1:41. PubMed
  114. Takimoto Y, et al. 2023. iScience. 26:106220. PubMed
  115. Wu Y, et al. 2023. Nat Cancer. 4:382. PubMed
  116. Willows JW, et al. 2023. iScience. 26:106189. PubMed
  117. Chung KJ, et al. 2023. Int J Mol Sci. 24:. PubMed
  118. Cui W, et al. 2023. J Exp Med. 220:. PubMed
  119. Ishida K, et al. 2023. Front Immunol. 14:1111729. PubMed
  120. Deng G, et al. 2023. Cancers (Basel). 15:. PubMed
RRID
AB_10899570 (BioLegend Cat. No. 103133)
AB_2562559 (BioLegend Cat. No. 103134)

Antigen Details

Structure
Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution

All hematopoietic cells except mature erythrocytes and platelets

Function
Phosphatase, T and B cell activation
Ligand/Receptor
Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1
Cell Type
B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85.
3. Kishihara K, et al. 1993. Cell 74:143.
4. Pulido R, et al. 1988. J. Immunol. 140:3851.

Gene ID
19264 View all products for this Gene ID
UniProt
View information about CD45 on UniProt.org

Related FAQs

What is the F/P ratio range of our BV421™ format antibody reagents?

It is lot-specific. On average it ranges between 2-4.

If an antibody clone has been previously successfully used in IBEX in one fluorescent format, will other antibody formats work as well?

It’s likely that other fluorophore conjugates to the same antibody clone will also be compatible with IBEX using the same sample fixation procedure. Ultimately a directly conjugated antibody’s utility in fluorescent imaging and IBEX may be specific to the sample and microscope being used in the experiment. Some antibody clone conjugates may perform better than others due to performance differences in non-specific binding, fluorophore brightness, and other biochemical properties unique to that conjugate.

Will antibodies my lab is already using for fluorescent or chromogenic IHC work in IBEX?

Fundamentally, IBEX as a technique that works much in the same way as single antibody panels or single marker IF/IHC. If you’re already successfully using an antibody clone on a sample of interest, it is likely that clone will have utility in IBEX. It is expected some optimization and testing of different antibody fluorophore conjugates will be required to find a suitable format; however, legacy microscopy techniques like chromogenic IHC on fixed or frozen tissue is an excellent place to start looking for useful antibodies.

Are other fluorophores compatible with IBEX?

Over 18 fluorescent formats have been screened for use in IBEX, however, it is likely that other fluorophores are able to be rapidly bleached in IBEX. If a fluorophore format is already suitable for your imaging platform it can be tested for compatibility in IBEX.

The same antibody works in one tissue type but not another. What is happening?

Differences in tissue properties may impact both the ability of an antibody to bind its target specifically and impact the ability of a specific fluorophore conjugate to overcome the background fluorescent signal in a given tissue. Secondary stains, as well as testing multiple fluorescent conjugates of the same clone, may help to troubleshoot challenging targets or tissues. Using a reference control tissue may also give confidence in the specificity of your staining.

How can I be sure the staining I’m seeing in my tissue is real?

In general, best practices for validating an antibody in traditional chromogenic or fluorescent IHC are applicable to IBEX. Please reference the Nature Methods review on antibody based multiplexed imaging for resources on validating antibodies for IBEX.

Go To Top Version: 3    Revision Date: 04/20/2022

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account